Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening.

ABSTRACT:

Importance

Previous research has shown good discrimination of short-term risk using an artificial intelligence (AI) risk prediction model (Mirai). However, no studies have been undertaken to evaluate whether this might translate into economic gains.

Objective

To assess the cost-effectiveness of incorporating risk-stratified screening using a breast cancer AI model into the United Kingdom (UK) National Breast Cancer Screening Program.

Design, setting, and participants

This study, conducted from January 1, 2023, to January 31, 2024, involved the development of a decision analytical model to estimate health-related quality of life, cancer survival rates, and costs over the lifetime of the female population eligible for screening. The analysis took a UK payer perspective,

SUBMITTER: Hill H 

PROVIDER: S-EPMC11377997 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature